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PKLR mutationAbstract Pyruvate Kinase (PK) deficiency is the most frequent red cell enzymatic defect responsi-
ble for hereditary non-spherocytic hemolytic anemia. The disease has been studied in several ethnic
groups. However, it is yet an unknown pathology in Tunisia. We report here, the phenotypic and
molecular investigation of PK deficiency in a Tunisian family.
This study was carried out on two Tunisian brothers and members of their family. Hematolog-
ical, biochemical analysis and erythrocyte PK activity were performed. The molecular characteriza-
tion was carried out by gene sequencing technique.
The first patient died few hours after birth by hydrops fetalis, the second one presented with
neonatal jaundice and severe anemia necessitating urgent blood transfusion. This severe clinical pic-
ture is the result of a homozygous mutation of PKLR gene at exon 8 (c.1079G>A; p.Cys360Tyr).
Certainly, this research allowed us to correlate the clinical phenotype severity with the identified
mutation. Moreover, this will help in understanding the etiology of unknown anemia in our
country.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Red blood cell Pyruvate Kinase (PK) deficiency (OMIM
266200) is the most common enzyme defect in the EmbdenMeyerhof pathway of glycolysis and one of the most common
causes of hereditary non-spherocytic hemolytic anemia in
humans. It was described for the first time in 1961 [1]. It is a
genetic defect transmitted as an autosomal recessive trait due
to several mutations at the Pyruvate Kinase gene (PKLR)
located on chromosome 1q21 [2]. The coding region is divided
into 12 exons, 10 of which are common to the two isoforms,
while exons 1 and 2 are specific for erythrocytic (PK-R) and
hepatic isoenzymes (PK-L) respectively [3–5]. The crystal
structure of the functional enzyme reveals that PK-R is a
homotetramer and each subunit consists of four domains
Figure 1 Pedigree of the studied family. The (c.G1079A)
mutation was identified at the homozygous state in the proband
IV-3 and his dead brother IV-2. It was heterozygous for both
parents (III-1 and III-2) and all other investigated members of the
family (I-1, II-2, II-3). The brother IV-1 exhibits a normal
genotype.
266 J. Mouna et al.(N, A, B and C domain) [6]. Domain A is the most highly
conserved whereas the B and C are more variable [7].
At the molecular level, more than 220 different mutations,
involving exons, introns and splice sites, have been described
so far in association with PK deficiency worldwide with several
recurrent mutations (www.lovd.nl.pklr). Among these, three
are reported to be the most prevalent in deficient patients in
different ethnic groups (1529A, 1456T and 1468T) [8–12].
Clinically, patients manifest a highly variable phenotype.
The degree of hemolysis fluctuates from mild or fully compen-
sated forms to whole life threatening anemia necessitating
exchange transfusions. In some severe conditions, individuals
may die in utero or at birth by hydrops fetalis [13–16].
In Tunisia, PK deficiency is yet poorly documented. Up to
date, only one reported case of Tunisian origin was described
on 2001 by Cotton et al. [17]. Deficient patients could die by
hydrops fetalis or in perinatal period. Moreover some of them
spend suffering for a long time without correct investigation.
Here in, we report the case of a severe hemolytic anemia due
to PK deficiency originated by a homozygous mutation in
the PKLR gene not yet reported in the Tunisian population.2. Subjects and methods
2.1. Subjects
This study was carried out on two brothers from consan-
guineous parents (Fig. 1). The first one IV-2 died few hours
after birth by hydrops fetalis. The second one IV-3 who was
born three years after, presented with neonatal jaundice and
deep anemia necessitating urgent blood transfusion. He was
transferred to neonatal intensive care for phototherapy and
further biological investigations.
After formal consent, the DNA of the dead baby IV-2
(obtained from DNA bank of the hospital) and blood samples
from the second proband IV-3 and his family (I-1, II-2, II-3,
III-1, III-2 and IV-1) were requested for further genetic analy-
sis (hemoglobinopathies, enzymopathies and Gilbert disease).
This study was approved by the Ethics Committee of Pasteur
Institute of Tunis, Tunisia in accordance with The Code of
Ethics of the World MEDICAL Association Declaration of
Helsinki.
2.2. Methods
2.2.1. Hematological and biochemical analysis
Red blood cell (RBC) indices and reticulocyte count have been
obtained automatically by a Coulter Counter (ABX pentra 60
C+, HORIBA Diagnostics). Coombs test, Blood smear, bone
marrow examination and other biochemical tests including
serum vitamin B12, ferritin level and bilirubin have been car-
ried out according to standard methods. Search for hemoglo-
binopathies (alpha and beta thalassemia, sickle cell disease)
was made using an HPLC analyzer D10 Hemoglobin testing
system (BioRad Laboratories, Hercules, CA, USA).
A purified RBC (without leukocytes and platelets) was pre-
pared for PK and glucose-6-phosphate dehydrogenase (G6PD)
assays, by passing the whole blood through a column contain-
ing alpha-cellulose and sigma-cellulose (Sigma–Aldrich).
Enzymatic assays and estimation of 2,3 bisphosphoglycerate(2,3 BPG) level were performed as described by Beutler et al.
[18].
2.2.2. Molecular investigations
Genomic DNA was isolated from peripheral blood leukocytes
by phenol/chloroform extraction according to standards pro-
tocols. The erythroid-specific promoter and exons of PKLR
gene, including flanking intronic regions, were amplified by
PCR as previously described [19].
The analysis of theA(TA)nTAAmotif in the promoter region
of the uridin-diphosphoglucuronyl transferase gene (UGT1-
A1), responsible of bilirubin glucuronidation, was performed
as described by Galanello et al. [20]. PCR was performed in
25 ll reaction volume containing 100 ng of genomic DNA,
0.2 mmol/l of each dNTP, 1 PCR buffer, 2.5 mmol/l MgCl2,
0.5 units of Taq DNA polymerase (Roche) and 10 pmol of
each primer (TAF: 50TCGTCCTTCTTCCTCTCTGG30 and
TAR: 50TCCTGCTCCTGCCAGAGGTT30). The PCR cycling
conditions included an initial denaturation step of 10 min at
96 C followed by 35 cycles of 96 C for 30 s, annealing at
58 C for 30 s and extension at 72 C for 1 min. The run was
ended by a final extension at 72 C for 7 min.
DNA sequencing was performed on an ABI PRISM 3600
DNA Analyser using ABI PRISMBigDye Terminator Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
3. Results
The clinical, biochemical, hematological and molecular inves-
tigations of the studied family are summarized in Tables 1
and 2.
3.1. Clinical, biochemical and hematological data
The proband IV-3 presented at birth with severe anemia and
neonatal jaundice. He received 12 blood transfusions during
the first fourteen months of his life. At the age of three years
and before any transfusion, the patient was diagnosed at the
Table 1 Hematological, biochemical data and hemoglobin
pattern of the proband IV-3.
Reference value
Hb (g/dL) 6.8 12–17.5
Retic (109/L) 240 25–86
MCV (fL) 82 82–98
MCH (pg) 28.8 27–32
MCHC (g/100 mL) 35.2 32–36
Ferritin (lg/L) 82.5 30–300
Vitamin B12 (pmol/L) 675 150–700
2,3 BPG (lmol/g Hb) 20 7.5–12
Total bilirubin (mg/L) 13 <10
Hb A (%) 97.5
Hb A2 (%) 2.5
Hb, hemoglobin; Retic, reticulocyte; MCV, Mean Corpuscular
Volume; MCH, Mean Corpuscular Hemoglobin; MCHC, Mean
Corpuscular Hemoglobin Concentration; 2,3 BPG, 2,3 biphos-
phoglycerate; Hb A, hemoglobin A; Hb A2, hemoglobin A2.
Pyruvate Kinase deficiency 267hematological, biochemical and molecular level. He presented
a severe hemolytic anemia with reticulocytosis, normal Mean
Corpuscular Volume (MCV), normal ferritin level and a nor-
mal Hemoglobin Pattern excluding an iron deficient anemia
and thalassemia. The direct Coombs test was negative. Thus,
the hemolytic anemia caused by immune system lysis was
excluded. Bone Marrow examination smear showed an
increased portion of erythroblasts (46%) with no specific
dyserythropoiesis.
Biochemical data of the proband indicated that the 2,3 bis-
phosphoglycerate (2,3 BPG) level is twofold increased compar-
ing to the normal range (20 lg/g Hb; instead of 7.5–12).
Further to that, total bilirubin level was high suggesting a pos-
sible Gilbert disease (Table 1).
The enzymatic assays showed normal G6PD level but
reduced PK activity (Table 2). At this step, our investigation
was oriented to the search of Gilbert disease, PK deficiency
or their co-inheritance.
The patient IV-2 died few hours after birth by hydrops feta-
lis. No other clinical and biological data are provided. The PK
activities of the parents and the great grand-mother I-1 are
reduced. However, the brother IV-1 had a normal PK activity
(Table 2).Table 2 Enzyme activity, clinical manifestations and genotype of t
P PK activity (IU/gHb)
(R.R: 5.2–8.5)
G6PD activity (IU/gHb)
(R.R: 5.26–7.94)
Clinical dat
IV-3 1.75 5.26 Neonatal ja
IV-2 ND ND Hydrops fet
IV-1 6.43 5.5 Normal
III-1 2.7 6.2 ND
III-2 2.68 5.8 ND
II-2 ND ND ND
II-3 ND ND ND
I-1 3.01 5.43 ND
P, patient; R.R, reference range; ND, no data; PK, Pyruvate Kinase; G63.2. Molecular analysis
Molecular analysis was performed for both Gilbert disease and
PK deficiency.
Analysis of the promoter region of the UGT1A1 gene in the
proband showed a normal polymorphic sequence A(TA)6-
TAA, excluding Gilbert disease. In fact, our molecular data
on this syndrome showed the association of a unique polymor-
phic sequence A(TA)7TAA with Gilbert syndrome among
Tunisians (Fig. 2) [21].
The screening of whole PKLR gene revealed the presence of
a G>A transition at nucleotide 1079 in the 8th exon (p.
Cys360Tyr). This mutation was identified at the homozygous
state in the proband IV-3 and his dead brother IV-2, whose
parents were related. It was heterozygous for both parents
(III-1 and III-2) and all other investigated members of the fam-
ily (I-1, II-2, II-3). The brother IV-1 exhibits a normal geno-
type (Fig. 3).
4. Discussion
PK deficiency, an autosomal recessive disorder, is probably the
most common cause of hereditary non-spherocytic hemolytic
anemia, often causing severe anemia from infancy or early
childhood [16]. The degree of consanguinity among parents
increases the risk of inheriting recessive disorders in their
children.
There are many and various mutations in the PKLR gene
described worldwide (www.lovd.nl.pklr). The present study
constitutes a complete phenotypical and molecular investiga-
tions of PK deficient patients in Tunisia and represents the first
description of the Cys360Tyr mutation at the homozygous
state worldwide. However, It was reported once in a com-
pound heterozygous state (Arg479His/Cys360Tyr) by Pissard
et al. [13,26].
PK deficiency remains misdiagnosed in our country. Sev-
eral deficient subjects develop transfusion dependent anemia
before to be treated by splenectomy [22,23] without correct
diagnosis. The most severe clinical complication of PK defi-
ciency is hydrops fetalis [15,24,25] that was observed in the
dead patient IV-2. The proband IV-3 displayed a severe hemo-
lytic anemia requiring regular blood transfusions. Fortunately,
he was early diagnosed and had regular medical follow up
based on transfusion therapy. The clinical severity of our
patients (IV-2 and IV-3) is most likely due to the homozygoushe studied family.
a Transfusion Genotype
undice and severe hemolytic anemia Yes 1079A/1079A
alis and neonatal death No 1079A/1079A
No No mutation
No 1079G/1079A
No 1079G/1079A
No 1079G/1079A
No 1079G/1079A
No 1079G/1079A
PD, glucose-6-phosphate dehydrogenase.
Figure 2 The ultrastructure of UGT1A1 gene showing the position of primers designed for PCR (A). The DNA sequence analysis of the
UGT1A1 promoter region (B).
Figure 3 Direct sequencing of exon 8 of PKLR gene in the proband and his family. The patients IV-2 and IV-3 appeared to be
homozygous for (c.1079A; pCys360Tyr) mutation (A); I-1, II-2, II-3, III-1 and III-2 are heterozygous (B); the brother IV-1 is normal (C).
268 J. Mouna et al.mutation (Cys360Tyr). It is a disruptive mutation associated
with a severe clinical expression. In fact, Pissard et al. in
2006 reported two different patients with different clinical pre-sentation, one of them presented with severe clinical presenta-
tion and was compound heterozygous (Cys360Tyr/
Arg479His), the second one, although homozygous for
Table 3 Effect of Cys360His and Arg479His mutations in the heterozygous/homozygous states.
Genotype Number
of cases
Hb
(g/dl)
Transfusion PK activity
(IU/g Hb)
Clinical manifestations References
Arg479His/
Cys360Tyr
1 6.4 - Transfusion in utero
- Severe anemia requiring 22 packed
RBC transfusion during 3 years
– Acute hemolysis during the third
trimester of pregnancy
[24,25]
2 (twins) – – – Neonatal death
Arg479His/
Arg479His
1 10 – 2.7 Neonatal anemia [24]
Cys360Tyr/
Cys360Tyr
Patient
IV-3
6.8 12 blood transfusion 1.75 Severe neonatal anemia and
neonatal jaundice
This study
Patient
IV-2
– – – Neonatal death by hydrops
fetalis
This study
Hb, hemoglobin; PK, Pyruvate Kinase.
Figure 4 Three dimensional crystal structure of human RPK
Cartoon drawing of the vicinity of the p.Cys360Tyr substitution.
The side chain of Tyr360 (depicted with dark gray) creates a steric
hindrance in the molecule, especially at the contact area of Tyr360
side chain and Leu327 residue. The figure was generated from the
atomic coordinates of protein data bank entry 1LIU [6] using the
program PyMOL (DeLano WL. The PyMOL molecular graphics
system, 2002 on World Wide Web http://www.pymol.org).
Pyruvate Kinase deficiency 269another mutation (Arg479His/Arg479His) exhibits a mild clin-
ical presentation (Table 3) [13]. This could lead to the conclu-
sion that Cys360Tyr mutation might be associated with the
severe clinical form of PK deficiency even at the homozygous
or compound heterozygous states.
The substituted Cys residue at position 360 is located in the
A domain (a6) of the PK subunit [6], which is the most highly
conserved domain [7]. Moreover, it contains residues involved
in the active site. Several studies have demonstrated that muta-
tions in A domain, especially in the homozygous form, are
associated with severe hemolytic anemia and necessity of trans-
fusion [6,13,19]. Furthermore, a number of mutations located
in the A domain (p.Asp331Gln; p.Gly341Asp and p.
Thr384Met) are associated with hydrops fetalis, such as the
case of our patient IV-2 [16,24]. These data confirm that thestructural alteration of this domain would result in severe
PK deficiency. In addition, the molecular modeling of this
mutation revealed that the Tyr360 side chain is buried in the
hydrophobic core of the molecule. A severe sterical hindrance
and unfavorable interactions were created between Tyr360 side
chain and Ile333, Met356, Val367 and especially Leu327 side
chains (Fig. 4).
The mutation described here is considered as one of the
more severe variants. Hence, identification of this type of
mutation is essential for accurate antenatal diagnosis. Its pres-
ence for at least three generations in a Tunisian family indi-
cates that we are probably in front of an ancient variant
whose origin could be explained by a founder effect within
the Tunisian population or by genetic flow through population
migration as it was assumed for sickle cell mutations and some
beta thalassemia alleles [27].
5. Conclusion
The description of these cases of PK deficiency in Tunisia
opens the access to the study of all ambiguous anemias at
the molecular level mainly at early age. Since only transfusion
therapy is available for the treatment of PK deficiency and sev-
ere cases may be improved by splenectomy. In the case of the
young patient described in this study, as anemia tends to
improve and stabilize with maturation, a few years of observa-
tion are necessary before making any decision.
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